Drug Type Small molecule drug |
Synonyms XY 153, XY-153, XY153 |
Target |
Action degraders |
Mechanism BRD4 degraders(Bromodomain-containing protein 4 degraders), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC33H34FN3O4 |
InChIKeyQSRRNUBIKNVQHO-UHFFFAOYSA-N |
CAS Registry2933176-32-8 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Preclinical | China | 25 Mar 2022 | |
| Adult Acute Myeloblastic Leukemia | Preclinical | China | 10 Dec 2020 |





